戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 [PhI(OTf)2] mediated oxidative coupling of 4-anilinoquinazoline-2-carbonitriles in neat trifluoroacet
2                                        The 4-anilinoquinazoline (4-AQ) derivative gefitinib (Iressa)
3 spectrometry and NMR studies demonstrated an anilinoquinazoline acrylate ester conjugate bound to EGF
4 of pp60(c-src) tyrosine kinase (Src TK) by 4-anilinoquinazolines, an important class of chemicals as
5 , a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible
6 y, efforts have been made to develop novel 4-anilinoquinazoline and pyridopyrimidine derivatives to i
7 rugs in the trypanosome, and (b) offer the 4-anilinoquinazoline and pyrrolopyrimidines as scaffolds w
8 t effects in the pendant anilino moiety of 4-anilinoquinazolines and 4-anilinoquinoline-3-carbonitril
9 ial for the apoptosis-inducing activity of 4-anilinoquinazolines and substitution in the 6- and 7-pos
10 ing Mycobacterium tuberculosis (Mtb), and an anilinoquinazoline (AQA) that also had potent activity a
11 ity relationships (SAR) of a novel series of anilinoquinazolines as allosteric inhibitors of fructose
12                  In contrast to the SAR of 4-anilinoquinazolines as EGFR kinase inhibitors, the methy
13 ssay, we have identified a novel series of 4-anilinoquinazolines as inducers of apoptosis.
14 ure-activity relationship (SAR) studies on 4-anilinoquinazolines as potent apoptosis inducers and to
15 F-R kinase with activity comparable to the 4-anilinoquinazoline-based inhibitors.
16                                        The 4-anilinoquinazolines canertinib and lapatinib, and the py
17 nvestigation is ZD1839 (Iressa), a synthetic anilinoquinazoline capable of inhibiting EGFR tyrosine k
18  inhibitors (TKIs), such as members of the 4-anilinoquinazoline class, competes for ATP binding.
19 mall-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.
20 hat has led to synthesis of several potent 4-anilinoquinazolines, including NEU617, 23a, a highly pot
21      Here we show that CI-1033 and related 4-anilinoquinazolines inhibit SPGF-induced human cellular
22 n with and without an EGFR kinase-specific 4-anilinoquinazoline inhibitor (erlotinib, Tarceva), we hy
23          We demonstrated recently that the 4-anilinoquinazolines lapatinib (GW572016, 1) and canertin
24 3-aminopropanamide linked in position 6 to 4-anilinoquinazoline or 4-anilinoquinoline-3-carbonitrile
25 different SAR as inhibitors of F16Bpase than anilinoquinazolines previously reported.
26                                            4-Anilinoquinazolines represent an important class of prot
27                                        The 4-anilinoquinazoline scaffold offers novel perspectives to
28 hibitors at the nanomolar range based on a 4-anilinoquinazoline scaffold.
29 he selectivity profile of molecules in the 4-anilinoquinazoline series can be modified through specif
30 istant clones are cross-resistant to related anilinoquinazolines, they demonstrate sensitivity to a c
31                                Previously, 4-anilinoquinazoline TKIs have been shown to inhibit the f
32   In both inhibitor/kinase structures, the 4-anilinoquinazoline was bound in the ATP site with the qu
33                                            4-Anilinoquinazolines with a bulky group at the 4'-positio
34 itors ZD1839 (Iressa) or PD153035, synthetic anilinoquinazolines with high specificity for EGFR, resu
35 pyrimidine PP1 and the clinically relevant 4-anilinoquinazoline ZD6474.